预约演示
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
临床1期临床2期并购抗体药物偶联物临床3期
The collaboration will aid in increasing the manufacture of the antibody intended for clinical development and commercialisation. Credit: Mike Mareen/ Shutterstock.com.
Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a potential treatment for Alzheimer’s disease (AD).
Acumen Pharmaceuticalsnces the manufacturing of sabirnetug for clinical development and poteLonza commercialisation, subject to sabirnetug (ACU193)Alzheimer’s disease (AD)
A humanised monoclonal antibody, sabirnetug targsabirnetugutralises toxic soluble amyloid beta oligomers (AβOs) implicated in the progression of AD.
Lonza will be responsible for thesabirnetugn of the drug at its facility in Portsmouth, New Hampshire, US. The unit is equipped with 2,000-litre (L) single-use bioreactors.
Lonzan will benefit from Lonza’s expertise in antibody manufacturing and extensive regulatory knowledge, as well as access to a manufacturing network capable of scaling from 2,000L to 20,000L.
Amylyx axes ALS drug from market after Phase III failure
Sabirnetug is the first humanised monoclonal antibody to show selective engagement with AβOs in a Phase I first-in-human clinical trial.
Daiichi Sankyo considered the initial catalyst and continuous driver of the synaptic dysfunction and neurodegeneration associated with AD, sabirnetug represents a therapeutic approach that addresses a fundamental cause of the disease.
It prevents the binding of toxic AβOs to dendritic spines, thereby preserving neuronal function.
Sabirnetugrmaceuticals president and chief development officer James Doherty stated: “As we progress into Phase II clinical development of sabirnetug as a potentially best-in-class treatment for early AD, we are acutely aware that patients and their families are in urgent need of safe, effective treatment options for this devastating disease.
“Partnering with Lonza is a critical step to ensure broader access to next-generation AD therapies.”sabirnetug
Last month, Lonza made a significant move by agreeing to purchase the Genentech large-scale biologics manufacturing facility in Vacaville, California, US, from Roche for $1.2bn.
Acumen Pharmaceuticalsstrengthen Lonza’s capacity for biologics production.sabirnetugearly AD
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。